Skip to main content
. Author manuscript; available in PMC: 2020 Jan 31.
Published in final edited form as: Oncogene. 2019 Oct 4;39(5):975–986. doi: 10.1038/s41388-019-1042-9

Figure 5. NRARP negative impact on primary T-ALL cells associates with Notch pathway activation status.

Figure 5

Analysis of primary and patient derived xenograft (PDX) T-ALL cell proliferation (A) and (B) viability upon delivery of NRARP recombinant protein (rNRARP). Samples with NOTCH1 mutations/high levels of NICD1 are depicted in orange and samples NOTCH1-WT/low levels of NICD1 in blue. (C) mRNA analysis of Notch1 and Wnt signaling transcriptional targets by quantitative PCR, in primary and PDX T-ALL cells treated with rNRARP. In (A) and (B) data represent the mean ± SEM. Statistical values were obtained using the Student’s t test. *p<0.05, **p<0.01